Parsippany-based specialty pharmaceutical company Actavis announced today its shareholders have approved several proposals related to the company's acquisition of Warner Chilcott. The approvals were required under closing conditions for the acquisition, which is expected to close early in the fourth quarter.
The acquisition, first announced in May, consists of a $5 billion stock swap of 0.16 of an Actavis share for each Chilcott share, valuing the Chilcott shares at $20.08 each. Current Actavis leadership will oversee the resulting company, Actavis PLC.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy